Amneal Pharmaceuticals (AMRX) reported Q4 adjusted earnings Friday of $0.12 per diluted share, down from $0.14 a year earlier.
Four analysts polled by FactSet expected $0.15.
Revenue for the quarter ended Dec. 31 was $730.5 million compared with $617 million a year earlier.
Three analysts surveyed by FactSet expected $708.1 million.
The company said it expects 2025 adjusted EPS of $0.65 to $0.70 on revenue of $3 billion to $3.1 billion. Analysts surveyed by FactSet expect $0.71 and $2.92 billion, respectively.
Amneal shares were up 2.6% in recent premarket activity.